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Abstract
Random chemical mutagenesis of the mouse genome can causally connect genes to specific phenotypes. Using this
approach, reduced pinna (rep) or microtia, a defect in ear development, was mapped to a small region of mouse
chromosome 2. Sequencing of this region established co-segregation of the phenotype (rep) with a mutation in the Prkra
gene, which encodes the protein PACT/RAX. Mice homozygous for the mutant Prkra allele had defects not only in ear
development but also growth, craniofacial development and ovarian structure. The rep mutation was identified as a
missense mutation (Serine 130 to Proline) that did not affect mRNA expression, however the steady state level of RAX
protein was significantly lower in the brains of rep mice. The mutant protein, while normal in most biochemical functions,
was unable to bind dsRNA. In addition, rep mice displayed altered morphology of the skull that was consistent with a
targeted deletion of Prkra showing a contribution of the gene to craniofacial development. These observations identified a
specific mutation that reduces steady-state levels of RAX protein and disrupts the dsRNA binding function of the protein,
demonstrating the importance of the Prkra gene in various aspects of mouse development.
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Introduction
The Prkra gene encodes a double-stranded RNA binding
protein, which was identified and named independently as Protein
Activator of PKR (PACT) in human [1], and PKR-associated
protein X (RAX) in mouse [2]. PACT and RAX are almost
identical in their amino acid sequences; only 6 out of 313 residues
are different with 4 substitutions being with similar residues. Initial
studies on this protein were focused on its ability to induce
autophosphorylation of and activate interferon inducible, double-
stranded RNA dependent protein kinase (PKR) (encoded by the
Eif2ak2 gene) in response to various stresses such as ceramide [3],
arsenite [2,4], tumor necrosis factor a (TNFa) [5], ethanol [6], low
dose actinomycin D [7], growth factor withdrawal [2,4],
chemotherapeutics [8], endoplasmic reticulum (ER) stress [9,10],
or peroxide [2,4]. Activation of PKR results in phosphorylation of
eukaryotic initiation factor 2a (eIF2a) leading to inhibition of
protein synthesis [11,12]. In addition to PACT/RAX, PKR is
modulated by another dsRNA binding protein, TAR (trans-
activating region) RNA-binding protein (TRBP in human, PRBP
in mouse) (encoded by the Tarbp2 gene) [13,14,15]. In contrast to
PACT/RAX, TRBP/PRBP inhibits PKR activation [14]. Aside
from binding PKR, PACT and TRBP have also been shown to
heterodimerize through interaction of their N-terminal dsRNA
binding motifs, as well as through their C-terminal Merlin-Dicer-
PACT liaison (Medipal) domain [16,17].
Upon appropriate stimulation, PACT is phosphorylated on
serine 246 and serine 287 [18], while RAX is phosphorylated on
serine 18 [19]. Phosphorylation causes PACT/TRBP heterodi-
mers to dissociate [20,21], freeing PACT to bind PKR through its
two amino-terminal double stranded RNA binding domains [7].
This leads to conformational change facilitating interaction of
PACT’s carboxy-terminal domain with the kinase domain of PKR
(residues 328–335) leading to PKR activation [16,22,23] and
subsequent eIF2a activation.
Studies in mice in which the Prkra gene was disrupted
(Prkra
tm1Gsc/tm1Gsc mice) produced unexpected results. In contrast
to mice in which the Eif2ak2 gene has been disrupted
(Eif2ak2
tm1Cwe/tm1Cwe), which had no discernable developmental
phenotype [24], Prkra
tm1Gsc/tm1Gsc mice showed defects in ear and
craniofacial development, growth and fertility [25]. Further
investigation revealed that Prkra
tm1Gsc/tm1Gsc mice developed
hypoplastic anterior pituitaries resulting from reduced cell
proliferation in this tissue [26]. As the anterior pituitary contains
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development, this likely accounts for some of the developmental
anomalies observed in the mouse [26].
In addition to its ability to activate PKR, PACT has also been
shown to have a role in production of small RNAs involved in
RNA silencing. PACT (as well as TRBP) interacts with Dicer,
which processes small RNAs from their precursor to mature forms,
and is a component of the RNA Induced Silencing Complex
(RISC) whose key components include Dicer and Argonaut
proteins [27]. While not essential for cleavage of pre-microRNAs
to their mature form by Dicer, PACT may be required for RISC
assembly, as depleting PACT led to reduced levels of mature
miRNAs in vitro [27]. While knockout mice for Dicer have been
generated, these are embryonically lethal [28]. The relevant tissue
specific knockouts for Dicer, however, [29,30] show similar
reproductive defects to the Prkra
tm1Gsc/tm1Gsc mice. This observation
supports the idea that at least some of the developmental defects
seen in the Prkra deficient mouse might result from defects in
miRNA processing.
In humans, mutations in Prkra are associated with Dyt16, an
autosomal recessive young onset dystonia-parkinsonism disorder
[31,32]. Dyt16 patients show retarded speech learning in infancy
and involuntary muscle contraction starting during teenage years.
The respective mutations correspond to a frameshift (266–
267delAT) causing premature termination of the protein [32]
and to a missense mutation P222L [31].
Ethylnitrosylurea (ENU) mutagenesis provides a mechanism for
generating random point mutations in the mouse germline [33].
Offspring of mice that have been mutagenized can be sequentially
crossed with wild-type mice to segregate mutated recessive alleles
and intercrossed to generate mice homozygous for the recessive
mutation [34]. The location of a mutation can then be mapped
within the genome and the mutated gene can be identified [34,35].
Subsequent to performing such a screen for dysmorphology one
mouse line named rep for ‘‘reduced pinna’’ was identified and
established carrying a recessive mutation in Prkra.
This study describes similarities and differences in the
phenotypes of the rep mutant mouse generated by ENU
mutagenesis and the existing Prkra null mutant mouse
(Prkra
tm1Gsc/tm1Gsc, described above) in which a portion of Exon 8
of Prkra was replaced with a neomycin resistance cassette [25].
This study demonstrates that the rep mutation produces a mutant
of the PACT/RAX protein which is present at significantly
reduced steady-state levels. This low level of PACT/RAX results
in a phenotype with many similarities to that of the Prkra
tm1Gsctm1Gsc
mouse in which no protein can be detected, in contrast to the
lethal effect observed in the deletion of the entire gene [36].
Results
Characterization of the reduced pinna recessive mutation
affecting the Prkra gene
In the course of the Phenotype Homozygote Mutants program
[34], the rep mutant mouse line which displays microtia (Figure 1A)
and growth retardation (Figure 2, Table 1) was isolated. The
mutation was induced by ENU on the C57BL/6J background and
was further established by backcrossing on the C3HeB/FeJ genetic
background. We used this backcross to precisely map the position
of the mutation using a panel of markers already described
[34,35]. The rep mutation was located between rs13476586 and
rs13476589 on mouse chromosome 2 (Figure 1B). Looking at
candidate genes in this region, we identified the Prkra gene for
which a knock-out displaying similar dysmorphology was previ-
ously described [25]. We sequenced the Prkra coding sequence and
exon/intron borders. We found a point mutation TRC in exon 4
affecting codon 130 and introducing the missense mutation S130P
(Figure 1C). Thus we conclude that the rep mutation affected the
Prkra gene so we named the mutation Prkra
rep. We verified that this
change was not found in either C57BL/6J or C3HeB/FeJ
background, or in other mouse strains including 129S2, BALB/c
and DBA2/J (data not shown). Performing a more detailed
phenotypic analysis we noticed two major changes in Prkra
rep/rep
homozygous mice. First, adult homozygous mice were smaller
compared to their control littermates (Table 1). The weight
difference was also found in younger individuals starting at 7 days
post partum, with no major difference between sexes in
homozygous mice (Figure 2). Second we noticed a defect in
fertility when we crossed the Prkra
rep/rep females with wild-type (wt)
or heterozygous mice. No progeny were obtained by breeding 7
homozygous females with wt males over a 2 month period.
Histopathological analysis of the ovaries showed all stages of
folliculogenesis from primordial to preovulatory follicles and
corpus luteum formation were present in mutant mice
(Figure 3A, B). No abnormalities were observed in the histology
of testes from male mutants (Figure 3C, D). We also observed
differences in the skull of rep homozygous mutants. We
characterized those changes by 3D-cranial morphology assessment
using a series of landmarks as indicated in the Materials and
Methods. Prkra
rep/+ (data not shown) and Prkra
rep/rep mouse skulls
were characterized by very short nasal bones (Figure 4A). They
also differed from the wt morphology by the shape of the
zygomatic process of the temporal bone which was relatively more
robust than the wt and their mandible differed from the wt by a
reduced coronoid process and a reduced mandibular condyle
(Figure 4A). Interestingly, Prkra
tm1Gsc/tm1Gscspecimens presented an
open area at the top of the skulls resulting from the lack of fusion of
the frontal and parietal bones. They also differed from the wt
morphology by a reduction of the interparietal bone associated
with a medial displacement of the parietal/interparietal/occipital
junction. Mandibles of homozygous specimens presented a
reduced mandibular condyle when compared to the wt specimens.
The cranial and mandibular morphologies of Prkra
rep/+ (data not
shown), Prkra
rep/rep and Prkra
tm1Gsc/tm1Gsc individuals differed from
the wt and also differed from one another (Figure 4B). These data
highlight that although phenotypes resulting from the Prkra
rep and
Prkra
tm1Gsc mutations share many common features, the mutations
have different impacts on cranial and mandibular morphology.
Presence of RAX mRNA in the brains of rep mice
To understand the physiological defects seen in rep mice it was
important to determine whether Prkra mRNA was present at wild-
type levels in these animals. It was possible that the S130P
mutation would alter the production, processing or stability of
Prkra mRNA. RT-PCR was used to determine whether Prkra
mRNA was produced in brain. Primer sequences targeting the 59
region (exons 2 and 3) and 39 region (exon 8) were used in separate
reactions to determine whether the entire mRNA or simply the
portion 59 of the T-C substitution leading to the S130P mutation
was generated. Both 59 and 39 portions of Prkra mRNA were
present in rep mice at levels comparable to those seen in wt mice,
indicating the S130P mutation does not impair production of full
length Prkra mRNA (Figure 5).
RAX (S130P) dimerizes and activates PKR in response to
stress, but is unable to bind dsRNA
To investigate the biochemical basis for the rep phenotype, the
S130P mutation was introduced in RAX for expression in mouse
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ability to bind and activate PKR, bind dsRNA and homodimerize.
The ability of RAX (S130P) to bind dsRNA was determined by
electrophoretic mobility shift assays using radiolabeled dsRNA and
bacterially-expressed, purified WT and mutant His-RAX. There
was a clear shift in electrophoretic mobility of the dsRNA probe in
the presence of 1 mM WT His-RAX which could be competed out
by unlabeled synthetic dsRNA, poly(I:C), demonstrating dsRNA
specific binding activity of WT RAX. The mutant protein
however could not bind dsRNA, as measured by this assay
(Figure 6A). To further examine this observation, a different
dsRNA-binding assay was used. In this assay, His-RAX was
incubated with radiolabeled dsRNA and then purified using Ni-
NTA agarose; the amount of dsRNA probe, bound to RAX, was
quantified by scintillation counting. Again, there was clear dsRNA
binding to the WT protein, which could be competed out with the
addition of unlabeled poly(I:C), while the mutant protein was
unable to bind the dsRNA probe (Figure 6B). These results
demonstrate that the S130P mutation disrupts the dsRNA binding
capacity of RAX.
Dimerization was examined by incubating purified WT or
S130P His-RAX with lysates from L929 cell lines expressing
similar levels of WT or S130P FLAG- RAX, as generated by
lentiviral transduction (Figure 6C, middle panels). Both WT and
mutant RAX homodimerized (Figure 6C, top panel) demonstrat-
Figure 1. Characterization and genetic identification of the rep
mutation. A 15dayspost-partum rep homozygous mice (right)displayed
reducedpinnacomparedtocontrollittermates(left).BHaplotypeanalysis
of 81 mutant mice derived from the outcross-intercross strategy. Markers
are shown with their position (cM) on chromosome 2 (Ensembl V50). The
C57BL/6J alleles are shown with black boxes whereas the white boxes
indicate the presence of the C3HeB/FeJ allele. Haplotypes with the same
allelic distribution were collected and their number is given at the top of
each column. C Sequence chromatograph spanning the rep mutation site
compared with that of a wild-type control.
doi:10.1371/journal.pone.0028537.g001
Figure 2. Growth curves of the rep homozygote mutants and
control littermates. Body weight curves of rep/rep individuals
generated from heterozygote intercrosses (male rep/rep n=9; male
wt n=15; female rep/rep n=12; female wt n=22) reveal that growth of
mutant homozygotes is affected during post-natal development
compared to control littermates.
doi:10.1371/journal.pone.0028537.g002
Table 1. Weights of adult rep mice compared to those of WT
controls
a.
Sex WT rep/rep P Value
Male 24.9+/22.1 g
n=11
19.2+/22.4 g
n=10
0.0013
Female 21.8+/21.1 g
n=8
17.5+/20.5 g
n=4
0.0005
aWeights of adult rep and WT littermates (male age 54 days+/21.4 days; female
age 54.3+/21.3 days) and the P-values of the corresponding Student T-test.
doi:10.1371/journal.pone.0028537.t001
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RAX.
To assess the ability of the S130P mutant protein to bind
PKR, cell lysates from WT or S130P FLAG-RAX expressing
L929 cells treated with sodium arsenite (to induce RAX
phosphorylation) were immunoprecipitated using a FLAG
antibody, followed by western blot for endogenous PKR. There
were clear interactions between PKR and WT or S130P RAX
proteins, independent of the arsenite treatment (Figure 6D),
demonstrating that the S130P mutation does not interfere with
PKR interaction of RAX.
For testing the ability of RAX (S130P) to activate PKR, we
generated L929 cells in which expression of RAX had been
ablated by a shRNA that targets the 39UTR of RAX mRNA. In
this cell line, WT or mutant RAX was ectopically expressed
using lentiviral vectors encoding the corresponding RAX
mRNAs without the UTRs (Figure 6E, bottom panel). These
cells were treated with sodium arsenite to activate RAX whose
ability to activate PKR was monitored by measuring eIF2a
phosphorylation; there were comparable stress-induced increases
in phospho-eIF2a in cells expressing WT or mutant RAX
(Figure 6E, top panel) demonstrating that the S130P mutation
does not impair the stress-induced PKR activation function of
RAX.
Reduced steady-state levels of ectopically expressed
mutant RAX
In L929 cells, ectopic expression levels of FLAG-RAX (S130P)
were consistently lower than those of WT FLAG-RAX (data not
shown). To determine whether the observed difference was
operative at the transcription or the translation level, we
measured the levels of RAX protein by western blot and mRNA
by realtime RT-PCR, in several cells lines that we generated. In
cells infected with RAX-expressing lentivirus at moi of 1, as
compared to WT, there was a slightly reduced level of the mutant
mRNA (Figure 7A) but an almost undectable level of the mutant
protein (Figure 7B). However, when the mutant-expressing virus
was used at a moi of 3, a comparable level of the mutant protein
was expressed from more than twice the level of the mutant
mRNA, indicating a defect in the synthesis or turnover of the
mutant protein. To distinguish between the two possibilities, we
measured the stability of the mutant protein in cells expressing
equal levels of WT and mutant proteins. New protein synthesis
was inhibited by cyclohexamide treatment, and the rate of decay
of existing RAX was monitored by western blot analysis at
different time points (Figure 7C). Data were quantified as FLAG
signals relative to actin signals (Figure 7D). We did not observe
any significant difference in the rates of WT and mutant protein
decay. These results indicate that the lower steady-state level of
Figure 3. Analysis of the gonads of rep/rep mutant mice. A, B Histological analysis of hematoxylin-stained sections. In ovaries, all stages of
folliculogenesis from primordial to preovulatory follicles and corpus luteum were observed in mutant mice (A) as in wild-type (B), suggesting that
ovaries are functional. Scale bar=150 mm. C Histology of the testis from adult rep mutant male. All stages of spermatogenesis were visible, and no
alteration of tubule diameter was observed. Scale bar=50 mm. D Histology of the cauda epididymis from adult rep mutant male. No abnormalities
were observed. Scale bar=20 mm.
doi:10.1371/journal.pone.0028537.g003
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not due to an accelerated decay.
Significantly reduced levels of mutant RAX in the brains
of rep mice
To extend our observations in cell lines to mice, we measured
RAX protein levels in brains of WT and rep mice; we chose the
brain as a representative tissue because RAX is highly expressed
there. Proteins precipitated from the trizol extracts of the brains of
the mice used to measure RAX mRNA levels (Figure 5) was used
to detect RAX protein levels by western blot, revealing
significantly reduced levels in mutant mice compared with WT
mouse (Figure 8A). To rule out the possibility that the reduced
protein levels were an artifact of precipitation from the trizol
fractionation, we prepared a third rep brain, along with WT and
tm1Gsc (RAX2/2) brains, using conventional detergent lysis.
These additional samples showed reduced mutant RAX protein in
the rep mouse and no RAX in the RAX2/2 mouse brains
(Figure 8B). These results, combined with those shown in Figure 5,
indicate that in rep mice much less RAX is present because of a
defect in the synthesis of the mutant protein.
Discussion
In this report we described the characterization of a new ENU-
induced missense mutation (S130P) in the coding sequence of the
Prkra gene. The new allele of the Prkra gene (rep) induces several
alterations in growth, and the development of the ear and skull of the
mutant mice. During this analysis we further characterized in rep
homozygous mutants, the craniofacial defects previously observed in
tm1Gscmice.Repmice were found to have a veryshortnasal bone and
a reduced coronoid processand mandibular condyle. Parallel analysis
carried out for the Prkra
tm1Gsc mutation revealed similar mandibular
alteration but major changes of the skull shape with a lack of fusion of
the frontal and parietal bones. Theseseries of data elaborate upon the
role of Prkra in controlling cranio-facial development.
Figure 4. Morphological variations observed in skulls and mandibles of wt, rep and Tm1Gsc mice. A Major cranial anomalies observed in
Prkra
rep and Prkra
tm1Gsc mice. Arrows indicate the principal defects for each mutant, i.e. the reduced coronoid process and mandibular condyle, and
the short nasal bone in rep mice and the bregmatic fontanelle-like structure of Prkra
tm1Gsc mice. Scale bar: 5 mm. B Plot of principal components 1
and 2 based on Procrustes analysis of 3D landmark coordinates of wt, rep and Prkra
tm1Gsc mice. Squares: wt mice; Triangles: Prkra
tm1Gsc mice; Filled
diamonds: rep heterozygous mice; Open diamonds: rep homozygous mice. On the principal components analysis (PCA) performed from cranial
landmarks (top panel), PC1 represents 54.7% of variance and PC2 15.1%. On the PCA performed from mandibular landmarks (bottom panel), PC1
represents 46.0% of variance and PC2 16.1%.
doi:10.1371/journal.pone.0028537.g004
Figure 5. Analysis of RAX mRNA expression in the brains of rep
mice. Total RNA was isolated from one WT and two rep mouse brains,
treated with DNase and analyzed by RT-PCR with appropriate primers
to measure the levels of the 59 region (exons 1 and 2) and the 39 region
(exons 7 and 8) of RAX mRNA. 18S rRNA was measured as a loading
control and –RT controls were used to ensure the absence of any
genomic DNA in the RNA preparations.
doi:10.1371/journal.pone.0028537.g005
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RAX (S130P) was incubated at the indicated concentration with 59end labelled dsRNA. In the indicated lanes, poly(I:C) was added to the reaction as a
competitor to demonstrate dsRNA-binding specificity. B DsRNA-pull-down assay: Purified His-RAX or His-RAX (S130P) was incubated with 59end
labelled dsRNA. His-RAX was pulled-down from the reactions with Ni-NTA agarose and bound dsRNA was measured by liquid scintillation (expressed
in counts per minute). CPM bound to BSA control has been subtracted from all lanes as background. C Dimerization assay: Purified His-RAX or His-
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domain of the protein and disrupts dsRNA binding without
affecting RAX dimerization or its ability to activate PKR. The
mutation also leads to a decrease in steady-state levels of RAX
protein, in tissue such as the brain, resulting in the phenotypes
observed in the rep mutant which are similar to those of a mouse
with a targeted disruption in the Prkra gene and as such the
phenotype is likely a result of the significantly reduced steady-state
protein level. At this time, we can not discern whether this is
connected to the inability of the mutant protein to bind dsRNA.
Another factor, that may play a role, is TAR RNA binding protein
(TRBP); its binding to PACT is partly mediated by the second
domain, the site of the S130P mutation [17].
Human TRBP and PACT directly interact with each other and
associate with Dicer to facilitate the production of small interfering
RNA [27,37]. Recently, Zehir et al. (2010) demonstrated that
controlled inactivation of Dicer in neural crest cells (which function
in skull development) results in craniofacial malformation [38].
The phenotypes we have observed in Prkra mutant mice may be
reminiscent of hypomorphic phenotypes of Dicer indicating that
defects in the miRNA pathway might contribute to the
craniofacial malformations we observed. As the rep mutation
disrupts dsRNA binding by RAX, there may be an effect on the
miRNA pathway in the rep mutant.
The rep mutant is, to our knowledge, the third allele of Prkra.
Rowe et al. (2006) published the Prkra
tm1Gsc mutant for Prkra with a
targeted disruption of the 39end of the gene that was used here
for comparison. Almost all the phenotypes present in the tm1Gsc
mouse were recapitulated to some extent in the rep mutant.
Interestingly the two mutations respectively affect the second and
the third RNA binding domains of the protein. In contrast,
deletion of the entire gene, Prkra
tm1Wsmay, engineered by Bennett
Figure 7. Reduced ectopic expression of RAX (S130P) in L929 cells. A RAX mRNA levels: Realtime RT-PCR analyses were used to determine
the levels of FLAG-RAX mRNA relative to 18S rRNA using RNA samples isolated from the indicated cells. B RAX protein levels: FLAG western blot of
L929 cells infected with empty lentivirus, or lentivirus encoding a provirus to ectopically express FLAG-RAX or FLAG-RAX (S130P) at the indicated MOI.
Three times more virus was required for FLAG-RAX (S130P) to achieve protein levels comparable to WT. C RAX turnover analyses: Cells were
treated with cycloheximide to inhibit de novo protein synthesis, cells lysates were prepared at the indicated time points and protein levels were
measured by Odyssey quantitative western blot of FLAG- RAX and FLAG-RAX (S130P) using actin as the internal control. D Normalized levels of
RAX: FLAG-RAX signal was normalized to that of actin and plotted at the indicated times following cycloheximide treatment.
doi:10.1371/journal.pone.0028537.g007
RAX (S130P) was incubated with lysates from L929 cells expressing empty provirus, FLAG-RAX or FLAG-RAX (S130P). His-RAX was pulled-down from
the reactions with Ni-NTA agarose and incubated with micrococcal nuclease to eliminate dsRNA-facilitated protein-protein interactions. Samples
were resolved by SDS-PAGE and subjected to western blotting with the indicated antibodies. Total input lysates were directly analyzed for measuring
the levels of expression of the indicated proteins. D PKR interaction assay: FLAG-RAX was immunoprecipitated with an agarose-conjugated
antibody against FLAG from lysates prepared from unstressed or arsenite treated L929 cells expressing empty provirus, FLAG-RAX or FLAG-RAX
(S130P). Immunoprecipitated samples were incubated with micrococcal nuclease to eliminate dsRNA-facilitated protein-protein interactions. Samples
were resolved by SDS-PAGE and PKR was detected by western blot to measure RAX-PKR interaction (top panel: PKR is the upper band and IgG is the
lower band (denoted by *)). Other panels show the levels of FLAG-RAX in the immunoprecipitates and the levels of PKR and actin in the input lysates.
E PKR activation assay: eIF2a phosphorylation was monitored by western blotting with a phospho-eIF2a-specific antibody (top panel). The middle
and the bottom panels show the levels of eIF2a and RAX respectively. In these experiments, expression of endogenous RAX had been ablated by
expressing a shRNA directed toward the 39UTR of the mRNA. In those cells, WT or mutant RAX was ectopically expressed using lentivirus vectors; cells
were stressed by treating them with sodium arsenite (100 mM), where indicated.
doi:10.1371/journal.pone.0028537.g006
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embryos detected after 3.5 days post conception. The less severe
phenotype seen in the Prkra
tm1Gsc and Prkra
rep mutants could occur
because these mutant proteins retain some function mediated by
the domains that have not been mutated. Indeed, although the
protein encoded by the Prkra
rep allele is deficient in dsRNA
binding, it still maintains dimerization activity and the ability to
activate PKR. Similarly, the Prkra
tm1Gsc transcript could poten-
tially be translated, although it contains multiple stop codons in
all 3 reading frames and has never yielded detectable protein
[25]. The mutant protein identified in rep and theoretically
present in tm1Gsc shared similar properties and activities
suggesting that a minimal level of expression of the RAX protein,
as observed in the rep homozygote animal, is necessary and
sufficient to rescue the early embryonic phenotypes observed in
Prkra
tm1Wsmay mutant.
The Prkra
tm1Gsc and Prkra
rep mutants represent a class of
hypomorphic allele with similar phenotypes affecting growth,
ear, craniofacial development, fertility and pituitary hormone
production (not shown). They should be considered as good
candidate models for studying Dystonia 16 (Dyt16) which is linked
to mutations in the human PRKRA gene leading to either
truncated form of the protein or changes in amino-acid sequences.
So far two mutations have been described in Dyt16 patients that
correspond to a frameshift (266–267delAT) causing premature
termination of the protein [32], and to a missense mutation P222L
[31]. These complementary data suggest that the strong
phenotype observed in the Prkra
tm1Wsmay allele is more a
consequence of the complete absence of RAX protein with no
residual activities rather than the inactivation of the first binding
domain. Until now the Prkra partial loss of function mutants have
been studied for other purposes but both models should be
explored further for traits observed in human patients to be
validated as a model for Dystonia 16.
Materials and Methods
Mice
The rep mutation was isolated from PhenHomut a genome wide
recessive mutagenesis program for phenotyping homozygote
mutants previously described [34,35]. The screening was oriented
toward recessive mutations affecting morphology, the cardiovas-
cular system, metabolism and the immune response. For rep,F 1
males, derived from the first progeny of ENU-treated C57BL/6J
(B6) males, were mated with wild-type females C3HeB/FeJ (C3H)
to generate G2 individuals. G3 individuals were derived from the
backcross of G2 females with the F1 males, and were screened
following a hierarchical and standardized phenotyping analysis.
We also took advantage of the backcross for the genetic mapping
and phenotypic analysis as described previously [34,35]. For
analysis of RAX expression, brains were dissected, snap-frozen
and stored in liquid nitrogen prior to isolation of RNA and/or
protein. All experiments were performed within the guidelines of
the French Ministry of Agriculture for experiments with laboratory
animals or in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocols were approved by the
Institutional Animal Care and Use Committee of Cleveland
Clinic (Approval Number ARC 08738) or the Ethical Committee
for the Region Centre to Y Herault (law 87 848; YH accreditation
45–31). All efforts were made to maximize animal welfare.
Phenotypic analysis of mice
Cohorts of age and sex-matched mutant and wild-type mice
were tested for a variety of phenotypic parameters according to the
standard operating procedures of the EUmorphia network
[34,35]. Mice were weighed daily to generate growth curves.
For histological analysis of gonads, tissues were fixed in Bouin’s
fixative, embedded in paraffin, sectioned at a thickness of 7 mm
and stained with hematoxylin. For X-ray analysis skulls were
preserved in 95% ethanol at 4uC prior to analysis.
To examine variations in skull and mandible shape, we used a
3D morphometric method based on landmark comparisons
adapted from Hallgrimsson et al. 2004 [39]. Landmarks were
taken on virtual reconstructions of the specimens’ skulls and
mandibles obtained by X-ray microtomography. The resulting
voxel size varied among specimens between 18 and 24 mm. The
skull and mandible surfaces were extracted using VGStudiomax
software. Twenty-two landmarks were defined using Landmark
software on each mandible and forty-nine on each skull (Figure
S1). Specimen size was normalised and landmarks from different
specimens superpimposed using the Procrustes method. Principal
Component Analyses was performed using Morphologika
2 v2.4
software using the full tangent space projection. Statistical tests
(MANOVA) were performed using Statistica software.
Plasmids, cell Lines and reagents
Mouse L929 and human HT1080 and HEK293T cell lines
were cultured in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum (Atlanta Biologicals) supplemented with
glucose (4.5 g/L), penicillin (50 U/ml), streptomycin (50 mg/ml),
L-glutamine (2 mM) and sodium pyruvate (1 mM). Sodium
arsenite was obtained from Sigma. Trizol reagent was obtained
from Invitrogen. The plasmids pLVX-IRES-ZsGreen1 and
pVSG-G were obtained from Clontech, pCMV-R8.74 was
obtained from Addgene, pET15b was obtained from Novagen,
pcDNA3 was obtained from Invitrogen, pLKO.1-puro was
obtained from Sigma.
Figure 8. Lower levels of RAX protein in the brains of rep mice.
A RAX levels in proteins recovered from the same samples
used for RAX mRNA measurements: Protein re-precipitated from
trizol extracts of the same brain preparations shown in Figure 5 was
analyzed by western blot for RAX and actin expression. B RAX levels in
conventional protein extracts of brains: RAX western blot from
brains homogenized and lysed in detergent-lysis buffer (see materials
and methods). RAX expression was analyzed in wild-type, Prkra
tm1Gsc
(denoted 2/2) and rep (denoted 3) mice.
doi:10.1371/journal.pone.0028537.g008
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The oligonucleotides AGC TTG GTA CCA TGG ACT ACA
AGG ACG ATG ACG ATA AGC ATG and GAT CCA TGC
TTA TCG TCA TCG TCC TTG TAG TCC ATG GTA CCA
were annealed and ligated into HindIII and BamHI digested
pcDNA3 (Invitrogen) using Rapid DNA Ligation Kit (Roche) to
generate pcDNA3-FLAG. RNA was extracted from L929 cells
using Trizol (Invitrogen) according to the manufacturer’s instruc-
tions, followed by DNAse treatment using DNA-free (Ambion)
according to manufacturer’s instructions. Extracted, DNase-
treated RNA was then reverse transcribed with the Superscript
III system (Invitrogen) using random hexamers according to
manufacturers instructions. The resulting cDNA was used to PCR
the coding sequence of RAX using the primers: 59 AGT AGT
GGA TCC ATG TCC CAT AGC AGG C and 39 AGT AGT
TCT AGA CTA CTT TCT TTC TGC TAT TAT C with
Expand High Fidelity PCR System (Roche), the PCR product was
then digested with BamHI and XbaI (New England Biolabs) and
ligated into BamHI-XbaI digested pcDNA3-FLAG with Rapid
DNA Ligation Kit (Roche), this clone was designated pcDNA3-
FLAG-RAX. pcDNA3-FLAG-RAX was used as a template in a
PCR reaction using the primers: 59 59AAC TCG AGG TAC CAT
GGA CTA CTA CAA GG and 39 AAT CTA GAG GAT CCC
TAC TTT CTT TCT GCT ATT ATC TTT AAA T with
Expand High Fidelity PCR System (Roche), the product was
digested with XhoI and XbaI (New England Biolabs) and ligated
into pLVX-IRES-ZsGreen1 (Clontech) with Rapid DNA Ligation
Kit (Roche) to generate pLVX-FLAG-RAX-IRES-ZsGreen1.
Mutation of FLAG-RAX
The S130P mutation was introduced to pLVX-FLAG-RAX-
IRES-ZsGreen1 by primer overlap mutagenesis, briefly one PCR
reaction was performed using the primers: 59AAC TCG AGG
TAC CAT GGA CTA CTA CAA GG and 39 GCT AAT TCC
TGT AAT GGG CCA ATT GGA TTC AGC TGG while a
second PCR reaction was performed using the primers: 59 CCA
ATT GGC CCA TTA CAG GAA TTA GCA ATT CAC CAT
Ga n d3 9 AAT CTA GAG GAT CCC TAC TTT CTT TCT
GCT ATT ATC TTT AAA T, both reactions were performed
using Expand High Fidelity PCR System (Roche). The resulting
overlapping PCR products were then used as template for a
second round PCR using the primers: 59 AAC TCG AGG TAC
CAT GGA CTA CTA CAA GG and 39 AAT CTA GAG GAT
CCC TAC TTT CTT TCT GCT ATT ATC TTT AAA T with
Expand High Fidelity PCR System (Roche), the mutagenized
product was digested with XhoI and XbaI (New England
Biolabs) and ligated into pLVX-IRES-ZsGreen1 (Clontech) with
Rapid DNA Ligation Kit (Roche) to generate pLVX-FLAG-
RAX(S130P)-IRES-ZsGreen1.
Construction of the RAX shRNA expression clone
The DNA oligonucleotides CCG GCC GTC AAC TTT CCA
GAT TTC TCG AGA AAT CTG GAA AGT TGA CGG TTT
TTG and AAT TCA AAA ACC GTC AAC TTT CCA GAT
TTC TCG AGA AAT CTG GAA AGT TGA CGG were
annealed and ligated into pLKO.1-puro digested with AgeI and
EcoRI (New England Biolabs) using Rapid DNA Ligation Kit
(Roche) to generate pLKO.1-RAX (1199)-puro.
Production of and infection with recombinant
lentiviruses
The lentiviral plasmids pLVX-IRES-ZsGreen1, pLVX-FLAG-
RAX-IRES-ZsGreen1, pLVX-FLAG-RAX (S130P)-IRES-ZsGreen1
or pLKO.1-RAX (1199)-puro were cotransfected with the
packaging plasmid pCMV-dR8.74 and the pseudotyping
plasmid pVSV-G by calcium phosphate into HEK293T cells.
Lentivirus-containing supernatants were harvested three times
every 12–16 hours, the collections were pooled, and the
lentivirus titered on HT1080 cells by estimating percentage
ZsGreen1 positive cells microscopically. L929 cells were infected
with recombinant lentivirus in complete DMEM (containing
10% FBS, penicillin and streptomycin) containing 8 mg/ml
polybrene (hexadimethrine bromide) for 24 hours before split-
ting into fresh media without polybrene and passaging as a
stable line. For RAX knockdown with pLKO.1-RAX (1199)-
puro, after 48 hours of recovery in complete DMEM,
puromycin was added at 5 mg/ml; after selection the cells were
grown in puromycin containing media as a stable line.
Bacterial expression and purification of recombinant RAX
pLVX-FLAG-RAX-IRES-ZsGreen1 was used as a template in
a PCR using the primers: 59 AAA AGC TTG GAT CCT ATG
TCC CAT AGC AGG CAT CG and 39 AAT CTA GAG GAT
CCC TAC TTT CTT TCT GCT ATT ATC TTT AAA T using
Expand High Fidelity PCR System (Roche), the product was
digested with BamHI (New England Biolabs) and ligated into
pET15b (Novagen) using Rapid DNA Ligation Kit (Roche) to
generate pET15b-RAX. pLVX-FLAG-RAX(S130P)-IRES-
ZsGreen1 was used as a template in a PCR using the primers:
59 AAA AGC TTG GAT CCT ATG TCC CAT AGC AGG
CAT CG and 39 AAT CTA GAG GAT CCC TAC TTT CTT
TCT GCT ATT ATC TTT AAA T using Expand High Fidelity
PCR System (Roche), the product was digested with BamHI (New
England Biolabs) and ligated into pET15b (Novagen) using Rapid
DNA Ligation Kit (Roche) to generate pET15b-RAX(S130P).
pET15b-RAX and pET15b-RAX(S130P) were transformed into
Rosettagami B(DE3) pLysS expression E. coli cells (Novagen).
These expression cells were grown to A600 of 1.0, at which time
IPTG (Denville) was added to 1 mM, the cells were incubated
shaking at room temperature for one hour. Induced cells were
collected by centrifugation, washed in cold PBS, and lysed in Ni-
NTA lysis buffer (20 mM Tris-HCl pH 7.5, 500 mM NaCl,
10 mM imidazole, 5 mM 2-mercaptoethanol, 0.1% NP-40,
100 mg/ml lysozyme, 10% glycerol, supplemented with complete
protease inhibitor tablet (Roche)). Cells were subjected to one
freeze-thaw cycle followed by lysis by sonication. Lysate was
clarified by centrifugation for 30 min at 200006g prior to binding
to Ni-NTA superflow resin (Qiagen). Protein-bound resin was
poured into a column and attached to an AKTA FPLC, the
column was washed to background with wash buffer (20 mM Tris-
HCl pH 7.5, 500 mM NaCl, 35 mM imidazole, 10% glycerol),
then eluted in a 10 ml linear gradient between wash buffer and
elution buffer (20 mM Tris-HCl pH 7.5, 500 mM NaCl, 300 mM
imidazole, 10% glycerol). Peak fractions were pooled and dialyzed
against dialysis buffer (20 mM Tris-HCl pH 7.5, 500 mM NaCl,
5 mM 2-mercaptoethanol, 10% glycerol).
RNA isolation, reverse transcription and RT-PCR
RNA was isolated from brains of wild-type, tm1Gsc or rep mice
using TRIZOL (Invitrogen) according to the manufacturer’s
instructions. RNA was isolated from L929 cell lines using
TRIZOL according to the manufacturer’s instructions. Following
RNA isolation, residual genomic DNA contamination was
removed by DNAse I treatment using DNA-free (Ambion).
RNA was reverse transcribed using the SuperScript III cDNA
First Strand Synthesis Kit (Invitrogen) according to manufacturer’s
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Clontech Advantage 2 Taq was performed using 18SrRNA
primers on DNAse treated RNA (withour reverse transcription)
and cDNA samples to determine the efficacy of DNAse treatment.
RT-PCR using this same protocol was used to amplify sequences
in the 59 and 39 regions of RAX, cDNA from 100 ng RNA was
used per amplification reaction, and the reaction cycle number
titrated for each primer set to determine the logarithmic range for
product growth. Cycling was as follows: 19 95uC, followed by
cycles of 19 95uC, 300 Tm,1 9 68uC, finishing with 59 68uC. Primer
sequences, melting temperatures and cycle numbers were as
follows:RAX Exons 2 and 3: 31 cycles, Tm=52uC. 59 primer TAA
GCC TGG GAA AAC ACC, 39 primer CCA GCT TCT TAC
TCG TAC CTT; RAX Exon 8: 30 cycles, Tm=60uC. 59primer
TCT CTT CAG ATT CCG TCA ACT TTC, 39 primer ACA
TTC ATC ACA AGC CTC AAC AC. 18S rRNA: 25 cycles,
Tm=55uC. 59 primer ATT GAC GGA AGG GCA CCA CCA G,
39 primer CAA ATC GCT CCA CCA ACT AAG AAC G.
Realtime PCR was performed using SYBR Green Core reagents
(Ambion) using 18S rRNA primers from RT-PCR method and
FLAG-PACT/RAX primers: 59 primer CTA CAA GGA CGA
TGA CGA TAA GC, 39 primer CAG CTT CTT ACT TGT
ACC TTC ACC. The reactions were run in a Roche Lightcycler
480, cycling was as follows: 39 95uC followed by 50 cycles of 300
95uC, 19 52uC, 300 72uC (SYBR green signal was acquired during
the 72uC incubation per cycle).
DsRNA electrophoretic mobility shift assay
The RNA oligonucleotide GGG AAC AAA AGC UGG GUA
CCG GGC CCC CCC was 59 end labelled using T4
polynucleotide kinase (Promega) according to the manufacturer’s
instructions. The oligonucleotide GGG GGG GCC CGG UAC
CCA GCU UUU GUU CCC was annealed to the radiolabelled
oligonucleotide and ethanol precipitated. His-RAX or His-
RAX(S130P) was added to binding buffer (20 mM Tris pH 7.5,
50 mM KCl, 2 mM MgCl2, 2 mM MnCl2, 5% glycerol) to the
indicated concentration along with 30000 cpm (25 fmol) labelled
dsRNA probe; for poly(I:C) competition, poly(I:C) was added to
10 ng/ml and incubated on ice for 10 minutes prior to adding
labelled probe. Binding reactions were incubated at room
temperature for 15 minutes, prior to loading on a gel of 0.256
TBE, 5% Acrylamide (37.5:1 acrylamide:bis-acrylamide) which
was run in cold buffer in a cold room.
DsRNA pull-down assay
Labelled dsRNA was incubated with His-RAX in binding buffer
(20 mM Tris pH 7.5, 50 mM KCl, 2 mM MgCl2, 2 mM MnCl2,
5% glycerol), the protein was pulled-down by Ni-NTA agarose,
washed and bound radioactivity was measured by scintillation
counting. Incubation with BSA was used to measure non-specific
binding of the probe and unlabelled poly(I:C) was used as a
competitor, where indicated.
Protein isolation and western blot
Protein was isolated from tissue by re-precipitating the organic
phase generated during TRIZOL (Invitrogen) RNA isolation
according to the manufacturer’s instructions. Briefly this
involved re-precipitation of protein using isopropanol followed
by washing with guanidine hydrochloride. Protein was isolated
from cultured cells and whole brain by washing in cold PBS
followed by lysis in Triton X-100 lysis buffer (20 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 5 mM
2-mercaptoethanol, 10% glycerol, supplemented with Complete
protease inhibitor tablet and PhoSTOP tablet (Roche). Where
indicated, sodium arsenite dissolved in water to 100 mM was
added to culture media to a final concentration of 100 mMf o r
one hour prior to harvesting cells. Protein was separated using
SDS-PAGE and transferred to PVDF membrane for western
blotting.
Antibodies
We used commercial antibodies to PACT/RAX [40], b-actin
(Clone AC-15, Sigma-Aldrich, A1978), FLAG (Clone M2, Sigma-
Aldrich, Catalog # F1804), P-eIF2a (Ser52) (Invitrogen, Catalog
# 44-728), eIF2a (Cell Signalling, Catalog # 9722), His Probe (H-
15, Santa Cruz Biotechnology, Catalog # sc-803), PKR (D-20,
Santa Cruz Biotechnology, Catalog # sc-708)
Immunoprecipitation and pulldown
FLAG-RAX was immunoprecipitated from cell lysates with
anti-FLAG M2 affinity gel (Sigma). Immunoprecipitation was
performed in Triton X-100 lysis buffer. Immunoprecipitated
samples were washed twice with lysis buffer then washed once
with 16 micrococcal nuclease buffer, resuspended in 50 ml1 6
micrococcal nuclease buffer containing 2000 gel units micrococ-
cal nuclease (New England Biolabs), and incubated at 37uCf o r
30 minutes. Samples were washed an additional two times before
separation by SDS-PAGE, and subsequent western blotting.
Recombinant 6xHis-tagged WT or mutant RAX (2 mg) were
incubated with 200 ng empty vector, FLAG-RAX or FLAG-
RAX (S130P) transduced L929 lysate in binding buffer (20 mM
Tris-HCl, 150 mM NaCl, 10 mM imidazole, 10% glycerol,
supplemented with complete protease inhibitor tablet and
PhoSTOP tablet (Roche)), the samples were then pulled-down
using Ni-NTA agarose (Qiagen). Two washes were performed
with binding buffer, then washed once in 16 micrococcal
nuclease buffer, resuspended in 50 ml1 6 micrococcal nuclease
buffer containing 2000 gel units micrococcal nuclease (New
England Biolabs), and incubated at 37uC for 30 minutes.
Samples were washed an additional four times with binding
buffer before separation by SDS-PAGE, and subsequent western
blotting.
FLAG-RAX decay kinetics
L929 cells expressing empty provirus, FLAG-RAX or FLAG-
RAX (S130P) were split into replicate plates and treated with
cycloheximide (100 mg/ml). Cells were lysed in Triton X-100 lysis
buffer at 0, 2, 4, 8, 12 or 24 hours following cycloheximide
treatment. Lysates were analyzed for FLAG-RAX by quantitative
western blot using the Odyssey infrared detection system (Licor;
IRDye 680 goat anti-rabbit for actin detection and IRDye 800
goat anti-mouse for FLAG detection). FLAG-RAX signal was
normalized to actin and the normalized signal was plotted as a
function of time.
Supporting Information
Figure S1 Landmarks used in morphological analysis of
the skull (shown only for left side). A Landmarks of the skull:1 .
nasale; 2. nasion; 3. bregma; 4. parietal-occipital junction; 5
midline of the interparietal-occipital junction; 6. dorsal midpoint
of the foramen magnum; 7. antero-lateral corner of the nasal; 8.
parietal-premaxillar-maxillar junction; 9. anterior-most point of
the zygomatic spine; 10. posterior-most point of the frontal-
maxillary dorsal junction; 11. Anterior-most point of the
squamosal-parietal junction; 12. anterior-most point of the
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alveoli; 14. anterior-most point of the anterior palatine foramen;
15. Ventral-most point of the premaxillar, maxillar and anterior
palatine foramen junction; 16. posterior-most point of the anterior
palatine foramen; 17. medial-most point of the first upper molar
cervix; 18. Point of greatest curvature of the posterior margin of
molar process; 19. distal-most point of the third upper molar
cervix; 20. Posterior-most point of the zygomatic fenetra on the
zygomatic process of the squamosal; 21. posterior-most point of
the zygomatic/squamosal junction; 22. Antero-medial projection
of ectotympanic in basicranial; 23. junction of basioccipital,
ectotympanic and basisphenoid; 24. Posterior edge of ectotympa-
nic along its margin with basioccipital; 25. anterior process of
auditory bulla; 26. ventral midpoint of the foramen magnum; 27.
Anterior-most point of the nasal/premaxillary junction; 28. dorsal-
most point of the incisor alveoli; 29; tip of the post-tympanic hook.
B Landmarks of the mandible: 1. tip of the coronoid process; 2. distal-
most point of the third lower molar cervix; 3. mesial-most point of
the first lower molar cervix; 4. dorsal-most point of the incisor
alveoli; 5. inferior-most point of the incisor alveoli; 6. Inferior-most
point of the mandibular symphysis; 7. Posterior-most point of
insertion site of mandibular transverse muscle; 8. tip of the
mandibular process; 9. ventral-most point of the mandibular
condyle; 10. anterior-most point of the mandibular condyle; 11.
posterior-most point of the mental foramen.
(TIF)
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